Pipeline / Therapeutic Platform / Tyvaso®

INCREASE - Phase 3 clinical trial with Tyvaso® (treprostinil) for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Dry Powder Inhaled (DPI) treprostinil in a small handheld device for the treatment of pulmonary arterial hypertension (PAH).

Phase 3 clinical trial with Tyvaso® (treprostinil) for the treatment of pulmonary hypertension due to chronic obstructive pulmonary disease (PH-COPD).

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Patients with Chronic Fibrosing Interstitial Lung Disease.